Related Experiment Video

Updated: Jul 3, 2026

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
09:10

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

Published on: October 28, 2019

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy

Sandra Turcotte1, Denise A Chan, Patrick D Sutphin

  • 1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Cancer Cell
|July 5, 2008
PubMed

Insights

Researchers discovered a new drug, STF-62247, that selectively kills cancer cells lacking the von Hippel-Lindau (VHL) gene. This targeted approach offers a promising new therapy for VHL-deficient renal cell carcinomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell carcinomas (RCCs) often resist conventional treatments.
  • Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is prevalent in 75% of RCC cases.
  • VHL deficiency drives tumorigenesis and impacts cellular pathways.

Purpose of the Study:

  • To identify small molecules that selectively target VHL-deficient RCC cells.
  • To investigate the mechanism of action of identified compounds.
  • To evaluate the therapeutic potential of novel agents against VHL-deficient RCC.

Main Methods:

  • High-throughput screening of small molecules to identify VHL-deficient cell-selective agents.
  • In vitro cytotoxicity assays comparing VHL-deficient and wild-type VHL cells.
  • Analysis of cellular pathways, including autophagy and HIF signaling.
  • Yeast deletion pool screening to identify genetic modifiers of drug sensitivity.

Main Results:

  • STF-62247 was identified as a potent VHL-deficient RCC cell-selective agent.
  • STF-62247 induced significant cytotoxicity and reduced tumor growth in VHL-deficient models.
  • The drug's efficacy was mediated through autophagy, independent of HIF signaling.
  • Genetic alterations in Golgi trafficking pathways enhanced sensitivity to STF-62247.

Conclusions:

  • STF-62247 represents a novel therapeutic strategy for VHL-deficient RCC.
  • Targeting VHL-deficient cells via autophagy modulation offers a new paradigm in cancer therapy.
  • Further investigation into STF-62247 and its mechanisms may lead to clinical applications.

More Related Videos

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.